LIfT BioSciences Ltd logo

LIfT BioSciences Ltd

LIfT BioSciences is developing portfolio of immuno-oncology cell therapies builds on innate cancer immunity and Leukocyte Infusion Therapy (LIfT). It is also developing worlds first cell bank of cancer killing Granulocytes (a type of white blood cell), to provide a range of potentially life-saving immuno-oncology cell therapies for different solid tumour types.

LIfT BioSciences was set-up with Prof Zhen Cui of Wake Forest University, a leading pioneer in LIFT, following his discovery of a cancer resistant (SR/CR) mouse that proved to have transferable innate immunity.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.liftbiosciences.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Eagle Labs, 81 Palace Gardens Terrace, Notting Hill Gate,,W8 4AT
London
United Kingdom
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/lift-biosciences-limited” connections=”true” suffix=””]

LIfTs innate immunity platform is known as Neutrophil only Leukocyte Infusion Therapy (N-LIfT), a first-in-class patented cell therapy. N-LIfT is produced ex-vivo and is highly scalable with potentially better and more consistent efficacy and safety than other forms of leukocyte infusion.

In March 2018, LIfT BioSciences successfully raised £300K in seed funding.